Log In
Print this Print this

Abasria, Basaglar, insulin glargine (LY2963016)

  Manage Alerts
Collapse Summary General Information
Company Eli Lilly and Co.
DescriptionBasal insulin analog
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat Type I and II diabetes; Treat Type I diabetes; Treat Type II diabetes
Regulatory Designation U.S. - Undisclosed Review (Treat Type I and II diabetes);
EU - Biosimilar (Treat Type I and II diabetes);
EU - Standard Review (Treat Type I and II diabetes)
Partner Boehringer Ingelheim GmbH

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
Get a free BioCentury trial today